title: Ionizing radiation predisposes nonmalignant human mammary epithelial cells to undergo transforming growth factor beta induced epithelial to mesenchymal transition.
abstract: Transforming growth factor beta1 (TGFbeta) is a tumor suppressor during the initial stage of tumorigenesis, but it can switch to a tumor promoter during neoplastic progression. Ionizing radiation (IR), both a carcinogen and a therapeutic agent, induces TGFbeta activation in vivo. We now show that IR sensitizes human mammary epithelial cells (HMEC) to undergo TGFbeta-mediated epithelial to mesenchymal transition (EMT). Nonmalignant HMEC (MCF10A, HMT3522 S1, and 184v) were irradiated with 2 Gy shortly after attachment in monolayer culture or treated with a low concentration of TGFbeta (0.4 ng/mL) or double treated. All double-treated (IR + TGFbeta) HMEC underwent a morphologic shift from cuboidal to spindle shaped. This phenotype was accompanied by a decreased expression of epithelial markers E-cadherin, beta-catenin, and ZO-1, remodeling of the actin cytoskeleton, and increased expression of mesenchymal markers N-cadherin, fibronectin, and vimentin. Furthermore, double treatment increased cell motility, promoted invasion, and disrupted acinar morphogenesis of cells subsequently plated in Matrigel. Neither radiation nor TGFbeta alone elicited EMT, although IR increased chronic TGFbeta signaling and activity. Gene expression profiling revealed that double-treated cells exhibit a specific 10-gene signature associated with Erk/mitogen-activated protein kinase (MAPK) signaling. We hypothesized that IR-induced MAPK activation primes nonmalignant HMEC to undergo TGFbeta-mediated EMT. Consistent with this, Erk phosphorylation was transiently induced by irradiation and persisted in irradiated cells treated with TGFbeta, and treatment with U0126, a MAP/Erk kinase (MEK) inhibitor, blocked the EMT phenotype. Together, these data show that the interactions between radiation-induced signaling pathways elicit heritable phenotypes that could contribute to neoplastic progression.
authors: Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, California, USA.
authors: Kumari L
authors: KL
authors: Andarawewa
authors: Anna C
authors: AC
authors: Erickson
authors: William S
authors: WS
authors: Chou
authors: Sylvain V
authors: SV
authors: Costes
authors: Philippe
authors: P
authors: Gascard
authors: Joni D
authors: JD
authors: Mott
authors: Mina J
authors: MJ
authors: Bissell
authors: Mary Helen
authors: MH
authors: Barcellos-Hoff
mesh_terms: D001940:Breast / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology / Q000528:radiation effects*; D002471:Cell Transformation, Neoplastic / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology / Q000528:radiation effects*; D004789:Enzyme Activation; D004847:Epithelial Cells / Q000187:drug effects / Q000473:pathology / Q000528:radiation effects; D006801:Humans; D020935:MAP Kinase Signaling System / Q000187:drug effects / Q000528:radiation effects; D008648:Mesoderm / Q000187:drug effects / Q000473:pathology / Q000528:radiation effects; D020929:Mitogen-Activated Protein Kinase Kinases / Q000378:metabolism; D016212:Transforming Growth Factor beta / Q000494:pharmacology*
chemical_list: D016212:Transforming Growth Factor beta; D020929:Mitogen-Activated Protein Kinase Kinases